|
KMID : 0981820100300010017
|
|
Korean Journal of Laboratory Medicine
2010 Volume.30 No. 1 p.17 ~ p.19
|
|
|
HDL Cholesterol Reduction during Rosiglitazone and Fenofibrate Treatment in a Type 2 Diabetes Mellitus Patient with Dyslipidemia
|
|
Im Mi-Jeong
Kim Min-Ki
Lee Jin-Kyung
Jang Yoon-Hwan
Lee Dong-Young
Hong Seok-Il
Hong Young-Jun
Lee Yun-Yong
|
|
|
Abstract
|
|
|
|
Thiazolidinediones (TZD), which are widely used as insulin sensitizers, and fibrates, which are lipid-lowering drugs, are used in the treatment of dyslipidemia that commonly accompanies diabetes. Several reports suggest elevated levels of high-density lipoprotein (HDL) cholesterol, but the paradoxical reduction of HDL cholesterol level during single or combined TZD and fibrate therapies has been occasionally reported. Herein, we report a case of paradoxical decrease in HDL cholesterol and apolipoprotein A-1 levels during rosiglitazone and fenofibrate treatment for the first time in Korea. The patient was a 56-yr-old man presenting with type 2 diabetes mellitus and dyslipidemia. His HDL cholesterol and apolipoprotein A-1 levels returned to normal after the cessation of fenofibrate therapy. Since diabetes is an established risk factor of cardiovascular diseases, low HDL cholesterol can be a key cause of concern for patients with diabetes. Therefore, HDL cholesterol level should be determined before and after starting TZD and/or fibrate therapy in diabetic patients.
|
|
|
KEYWORD
|
|
|
HDL cholesterol, Rosiglitazone, Fenofibrate
|
|
|
FullTexts / Linksout information
|
|
 
|
|
|
Listed journal information
|
|
  
|